Effects of antihypertensive drugs on endothelial dysfunction: Clinical implications

Drugs

Volumn 62, Issue 2, 2002, Pages 265-284

  Taddei, Stefano ^a   Virdis, Agostino ^a   Ghiadoni, Lorenzo ^a   Sudano, Isabella ^a   Salvetti, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ARGININE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; LACIDIPINE; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGEN RADICAL; PROSTAGLANDIN H2; SUPEROXIDE; TETRAHYDROBIOPTERIN; THROMBOXANE A2; UNINDEXED DRUG;

ANTIHYPERTENSIVE THERAPY; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL TONE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0036179826     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262020-00003     Document Type: Review

References (116)

1. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
2. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
3. Vascular endothelial cells synthesize nitric oxide from L-arginine
4. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase
5. Endothelium-dependent hyperpolarization-beyond nitric oxide and cyclic GMP
6. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
7. The human endothelin family: 3 Structurally and pharmacologically distinct isopeptides predicted by 3 separate genes
8. A membrane bound metalloprotease that catalyses the proteolytic activation of big endothelin-1
9. Cloning and expression of a cDNA encoding an endothelin receptor
10. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels
11. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo
12. Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells: Receptor coupling to nitric oxide synthase
13. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor
14. Endothelin as a regulator of cardiovascular function in health and disease
15. Endothelium-dependent contractions to arachidonic acid are mediated by products of cyclooxygenase
16. Superoxide anion is an endothelium-derived contracting factor
17. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
18. Indirect evidence for the release of endothelium-derived relaxing factor in the human forearm circulation in vivo: Blunted response in essential hypertension
19. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension
20. Vasodilation to acetylcholine in primary and secondary forms of human hypertension
21. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension
22. Effect of insulin on acetyl-choline-induced vasodilation in normotensive subjects and patients with essential hypertension
23. Aging and endothelial function in normotensive subjects and essential hypertensive patients
24. Hypertension causes premature aging of endothelial function in humans
25. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension
26. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension
27. Impaired endothelial function in arterial hypertension and hypercholesterolemia: Potential mechanisms and differences
28. G-monomethyl-L-arginine in patients with hypertension: The nitric oxide dilator mechanism appears abnormal
29. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired NO availabitity in essential hypertensive patients
30. Basal nitric oxide synthesis in essential hypertension
31. Impaired endothelium-dependent vasodilation in patients with essential hypertension: Evidence that the abnormality is not at the muscarinic receptor level
32. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension
33. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients
34. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients
35. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
36. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis
37. Role of endothelin-1 in hypertension
38. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension
39. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide
40. Endothelin-A receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade
41. Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells
42. Angiotensin II mediated hypertension in rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alteration of vasomotor tone
43. The functional role of angiotensin II subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts
44. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium
45. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
46. Nitric oxide inhibits angiotensin II induced migration of vascular smooth muscle cells
47. Nitric oxide: An endogenous modulator of leucocyte adhesion
48. Nitric oxide decreases cytokine-induced endothelial activation
49. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women
50. Menopause is associated with endothelial dysfunction in normotensive and essential hypertensive humans
51. Impaired vasodilation of forearm resistance vessels in hyperchotesterolemic humans
52. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients
53. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults
54. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus
55. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus
56. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans
57. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans
58. Endothelial function and common carotid artery wall thickening in patients with essential hypertension
59. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis
60. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant
61. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
62. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
63. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain
64. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension
65. Effect of captopril and enalapril on endothelial function in hypertensive patients
66. Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension
67. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats
68. Close relationship of endothelial function in the human coronary and peripheral circulations
69. Structure and function of resistance arteries of hypertensive patients treated with a β-blocker or a calcium channel antagonist
70. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients
71. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries
72. Nebivolol vasodilates human forearm vasculature: Evidence for an L-arginine/NO-dependent mechanism
73. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension
74. Carvedilol improves endothelial dysfunction in patients with essential hypertension
75. 2+-antagonists
76. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril
77. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension
78. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension
79. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)
80. The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension
81. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: A multicenter study
82. Role of nitric oxide in reactive hyperemia in human forearm vessels
83. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients
84. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients
85. Intracellular calcium, current and stimulus-response coupling in endothelial cells
86. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with α-tocopherol
87. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells
88. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension
89. Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids
90. Isradipine improves endothelium-dependent vasodilation in normotensive coronary artery disease patients with hypercholesterolemia
91. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia
92. Correction of remodeling and function of small arteries in human hypertension by cilazapril, an angiotensin I-converting enzyme inhibitor
93. Comparison of effects of angiotensin I-converting enzyme inhibition and β-blockade for 2 years on function of small arteries from hypertensive patients
94. Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy
95. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients
96. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study
97. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: Role of superoxide dismutase
98. Contrasting effect of antihypertensive treatment on the renal response to L-Arginine
99. Effect of cilazapril on vascular structure and function in essential hypertension
100. Effect of lisinopril on endothelial function
101. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: A novel autocrine function
102. Role of prostanoids in renin-dependent and renin-independent hypertension
103. The endothelial cell nitric oxide synthase: Is it really constitutively expressed?
104. Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats
105. Coronary kinin generation mediated nitric oxide release after angiotensin receptor stimulation
106. Losartan inhibits thromboxane A2-platelet aggregation and vascular constriction in spontaneously hypertensive rats
107. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan
108. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension
109. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis
110. 1999 Guidelines for the management of hypertension
111. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease
112. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women
113. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1
114. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) study
115. Coagulation activation following estrogen administration to postmenopausal women